Clinical prospects of NF-κB inhibitors to further targeted therapies in rheumatology

Contemporary Targeted Therapies in Rheumatology

Volumn , Issue , 2007, Pages 581-600

  Drexler, Stefan K ^a   Turner, Jeremy J O ^a   Foxwell, Brian M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37149018293     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (171)

1. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9: 1245-50.
2. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
3. Feldmann M, Brennan FM, Foxwell BM et al. Anti-TNF therapy: where have we got to in 2005? J Autoimmun2005; 25 (Suppl): 26-8.
4. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
5. Campion GV, Lebsack ME, Lookabaugh J et al. Doserange and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996; 39: 1092-101.
6. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebocontrolled trial. Arthritis Rheum 2004; 50: 1761-9.
7. Feldmann M, Brennan FM, Williams RO et al. The transfer of a laboratory based hypothesis to a clinically useful therapy: The development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol2004; 18: 59-80.
8. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
9. Kovacsovics T, Maziarz RT. Philadelphia chromosomepositive acute lymphoblastic leukemia: impact of imatinib treatmenton remission induction and allogeneic stem cell transplantation. Curr Oncol Rep 2006; 8: 343-51.
10. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-7.
11. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
12. Verma IM, Stevenson JK, Schwarz EM et al. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9: 2723-35.
13. Thompson JE, Phillips RJ, Erdjument-Bromage H et al.I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 1995; 80: 573-82.
14. Tran K, Merika M, Thanos D. Distinct functional properties of IkappaB alpha and IkappaB beta. Mol Cell Biol1997; 17: 5386-99.
15. Bitko V, Barik S. Persistent activation of RelA by respiratory syncytial virus involves protein kinase C, under-phosphorylated IkappaBbeta, and sequestration of protein phosphatase 2A by the viral phosphoprotein. J Virol 1998; 72: 5610-18.
16. Blackwell TS, Stecenko A A, Christman JW. Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol 2001; 281: L69-70.
17. DeLuca C, Petropoulos L, Zmeureanu D et al. Nuclear IkappaBbeta maintains persistent NF-kappaB activation in HIV-1-infected myeloid cells. J Biol Chem 1999; 274: 13010-16.
18. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest2001; 107: 143-51.
19. Johnson DR, Douglas I, Jahnke A et al. A sustained reduction in IkappaB-beta may contribute to persistent NF-kappaB activation in human endothelial cells. J Biol Chem 1996; 271: 16317-22.
20. Palmer GH, Machado J Jr, Fernandez P et al.Parasite-mediated nuclear factor kappaB regulation in lymphoprolifération caused by Theileria parva infection. Proc Natl Acad Sci U S A 1997; 94: 12527-32.
21. Stecenko AA, King G, Torii K et al. Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation 2001; 25: 145-55.
22. Kearns JD, Basak S, Werner SL et al. IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. J Cell Biol 2006; 173: 659-64.
23. Bours V, Franzoso G, Azarenko V et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993; 72: 729-39.
24. Nolan GP, Fujita T, Bhatia K et al. The bcl-3 protooncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 1993; 13: 3557-66.
25. Fujita T, Nolan GP, Liou HC et al. The candidate protooncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev 1993; 7: 1354-63.
26. Heissmeyer V, Krappmann D, Wulczyn FG et al.NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J 1999; 18: 4766-78.
27. Franzoso G, Bours V, Park S et al. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature 1992; 359: 339-42.
28. Dechend R, Hirano F, Lehmann K et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 1999; 18: 3316-23.
29. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
30. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
31. O'Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003; 3: 396-403.
32. Yamazaki S, Muta T, Takeshige K. A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J Biol Chem 2001; 276: 27657-62.
33. Kitamura H, Kanehira K, Okita K et al. MAIL, a novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production. FEBS Lett 2000; 485: 53-6.
34. Haruta H, Kato A, Todokoro K. Isolation of a novel interleukin-1-inducible nuclear protein bearing ankyrin-repeat motifs. J Biol Chem 2001; 276: 12485-8.
35. Yamamoto M, Yamazaki S, Uematsu S et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 2004; 430: 218-22.
36. Hirotani T, Lee PY, Kuwata H et al. The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol2005; 174: 3650-7.
37. Kuwata H, Matsumoto M, Atarashi K et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity2006; 24: 41-51.
38. Karin M, Ben-Neriah Y. Phosphorylation meets ubiqui-tination: The control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63.
39. Rothwarf DM, Zandi E, Natoli G et al. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998; 395: 297-300.
40. Makris C, Godfrey VL, Krahn-Senftleben G et al. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 2000; 5: 969-79.
41. Li Q, Van Antwerp D, Mercurio F et al. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284: 321-5.
42. Li ZW, Chu W, Hu Y et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999; 189: 1839-45.
43. Chen LW, Egan L, Li ZW et al. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9: 575-81.
44. Hu Y, Baud V, Delhase M et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 1999; 284: 316-20.
45. Hu Y, Baud V, Oga T et al. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature2001; 410: 710-14.
46. Lawrence T, Bebien M, Liu GY et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138-43.
47. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 (Suppl): S81-S96.
48. Dejardin E, Droin NM, Delhase M et al. The lympho-toxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity2002; 17: 525-35.
49. Senftleben U, Cao Y, Xiao G et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001; 293: 1495-9.
50. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
51. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
52. Schmitz ML, Mattioli I, Buss H et al. NF-kappaB: A multifaceted transcription factor regulated at several levels. Chembiochem 2004; 5: 1348-58.
53. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 2002; 21: 6539-48.
54. Kiernan R, Bres V, Ng RW et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003; 278: 2758-66.
55. Chen LF, Williams SA, Mu Y et al. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005; 25: 7966-75.
56. Kucharczak J, Simmons MJ, Fan Y et al. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961-82.
57. Fujita T, Nolan GP, Ghosh S et al. Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev 1992; 6: 775-87.
58. Kunsch C, Ruben SM, Rosen CA. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol 1992; 12: 4412-21.
59. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. EMBO J 2003; 22: 5530-9.
60. Berkowitz B, Huang DB, Chen-Park FE et al. The x-ray crystal structure of the NF-kappa B p50.p65 heterodimer bound to the interferon beta -kappa B site. J Biol Chem 2002; 277: 24694-700.
61. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene 1999; 18: 6845-52.
62. Chen-Park FE, Huang DB, Noro B et al. The kappa B DNA sequence from the HIV long terminal repeat functions as an allosteric regulator of HIV transcription. J Biol Chem 2002; 277: 24701-8.
63. Escalante CR, Shen L, Thanos D et al. Structure of NF-kappaB p50/p65 heterodimer bound to the PRDII DNA element from the interferon-beta promoter. Structure 2002; 10: 383-91.
64. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
65. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A 1989; 86: 2336-40.
66. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol2006; 18: 3-9.
67. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005; 26: 447-54.
68. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-76.
69. Kopp E, Medzhitov R, Carothers J et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev 1999; 13: 2059-71.
70. Liu ZG, Hsu H, Goeddel DV et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996; 87: 565-76.
71. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science1996; 274: 782-4.
72. Van Antwerp DJ, Martin SJ, Kafri T et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science1996; 274: 787-9.
73. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-7.
74. Kamata H, Honda S, Maeda S et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120: 649-61.
75. Pham CG, Bubici C, Zazzeroni F et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004; 119: 529-42.
76. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
77. Covert MW, Leung TH, Gaston JE et al. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005; 309: 1854-7.
78. Andreakos E, Sacre S, Foxwell BM et al. The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front Biosci 2005; 10: 2478-88.
79. Asahara H, Asanuma M, Ogawa N et al. High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 1995; 37: 827-32.
80. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38: 1762-70.
81. Marok R, Winyard PG, Coumbe A et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583-91.
82. Drent M, van den Berg R, Haenen GR et al. NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 50-6.
83. Foxwell B, Browne K, Bondeson J et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A 1998; 95: 8211-15.
84. Bondeson J, Foxwell B, Brennan F et al. Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares antiinflammatory mediators. Proc Natl Acad Sci U S A 1999; 96: 5668-73.
85. Amos N, Lauder S, Evans A et al. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology (Oxford) 2006; 45: 1201-9.
86. Andreakos E, Smith C, Kiriakidis S et al. Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003; 48: 1901-12.
87. Andreakos E, Smith C, Monaco C et al. Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood 2003; 101: 983-91.
88. Iotsova V, Caamano J, Loy J et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3: 1285-9.
89. Jimi E, Aoki K, Saito H et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10: 617-24.
90. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem 2000; 275: 3687-92.
91. de Crombrugghe B, Lefebvre V, Behringer RR et al.Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol 2000; 19: 389-94.
92. Benito MJ, Murphy E, Murphy EP et al. Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1781-7.
93. Campbell IK, Gerondakis S, O'Donnell K et al. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000; 105: 1799-806.
94. Seetharaman R, Mora AL, Nabozny G et al. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. J Immunol 1999; 163: 1577-83.
95. Palombella VJ, Conner EM, Fuseler JW et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998; 95: 15671-6.
96. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8.
97. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-7.
98. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006; 33: 722-31.
99. Cronstein BN, Montesinos MC, Weissmann G. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A 1999; 96: 6377-81.
100. Kang BY, Chung SW, Im SY et al. Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology 1999; 98: 98-103.
101. Hayashi R, Wada H, Ito K et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51-62.
102. Auphan N, DiDonato JA, Rosette C et al.Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-90.
103. Scheinman RI, Cogswell PC, Lofquist AK et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6.
104. Drouin J, Sun YL, Chamberland M et al. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J 1993; 12: 145-56.
105. Sakai DD, Helms S, Carlstedt-Duke J et al. Hormonemediated repression: A negative glucocorticoid response element from the bovine prolactin gene. Genes Dev1988; 2: 1144-54.
106. Webster JC, Cidlowski JA. Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol Metab 1999; 10: 396-402.
107. Hermoso MA, Cidlowski JA. Putting the brake on inflammatory responses: The role of glucocorticoids. IUBMB Life 2003; 55: 497-504.
108. D'Acquisto F, Ianaro A. From willow bark to peptides: The ever widening spectrum of NF-kappaB inhibitors. Curr Opin Pharmacol 2006; 6: 387-92.
109. Bateman E, Karpel J, Casale T et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006; 129: 1176-87.
110. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 1997; 100: 1863-9.
111. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003; 7: 369-79, vi.
112. Hofmann CA, Edwards CW 3rd, Hillman RM et al.Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinology 1992; 130: 735-40.
113. Oakes ND, Kennedy CJ, Jenkins AB et al. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-10.
114. Cuzzocrea S, Mazzon E, Dugo L et al. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2003; 48: 3544-56.
115. Lewis JD, Lichtenstein GR, Stein RB et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001; 96: 3323-8.
116. Hartung DM, Touchette DR, Bultemeier NC et al. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: A Medicaid claims-based case-control study. Pharmacotherapy 2005; 25: 1329-36.
117. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetic Med2005; 22: 973-9.
118. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-12.
119. Aljada A, Garg R, Ghanim H et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?J Clin Endocrinol Metab 2001; 86: 3250-6.
120. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-35.
121. Hershfield NB. Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18: 101-4.
122. Yasui K, Kobayashi N, Yamazaki T et al. Thalidomide as an immunotherapeutic agent: The effects on neutrophilmediated inflammation. Curr Pharm Des 2005; 11: 395-401.
123. Kim YS, Kim JS, Jung HC et al. The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line. Mol Cells 2004; 17: 210-16.
124. Jin SH, Kim TI, Han DS et al. Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. Ann N Y Acad Sci 2002; 973: 414-18.
125. Bariol C, Meagher AP, Vickers CR et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol2002; 17: 135-9.
126. Lipsky PE, Tao XL. A potential new treatment for rheumatoid arthritis: Thunder god vine. Semin Arthritis Rheum 1997; 26: 713-23.
127. Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. J Pharmacol Exp Ther 1995; 272: 1305-12.
128. Qiu D, Zhao G, Aoki Y et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expressi on at the level of purin e-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274: 13443-50.
129. Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 2003; 4: 1-18.
130. Jiang XH, Wong BC, Lin MC et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001; 20: 8009-18.
131. Tao X, Younger J, Fan FZ et al. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebo-controlled study. Arthritis Rheum 2002; 46: 1735-43.
132. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
133. Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl 2): ii86-9.
134. Burke JR, Pattoli MA, Gregor KR et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003; 278: 1450-6.
135. Rhee JW, Lee KW, Sohn WJ et al. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappaB in response to CpG-oligodeoxy-nucleotides in RAW 264.7 cells. Mol Immunol 2007; 44: 1393-400.
136. McIntyre KW, Shuster DJ, Gillooly KM et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum2003; 48: 2652-9.
137. Wen D, Nong Y, Morgan JG et al. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 2006; 317: 989-1001.
138. Catley MC, Sukkar MB, Chung KF et al. Validation of the anti-inflammatory properties of small-molecule IkB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 2006; 70: 697-705.
139. Alkalay I, Yaron A, Hatzubai A et al. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1995; 92: 10599-603.
140. Spano JP, Bay JO, Blay JY et al. Proteasome inhibition: A new approach for the treatment of malignancies. Bull Cancer 2005; 92: E61-6, 945-52.
141. Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-72.
142. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol2005; 23: 676-84.
143. Hattori Y, Sakaguchi M, Maitani Y. Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells. Biol Pharm Bull 2006; 29: 1516-20.
144. Lin YZ, Yao SY, Veach RA et al. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem1995; 270: 14255-8.
145. Ledeboer A, Gamanos M, Lai W et al. Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur J Neurosci 2005; 22: 1977-86.
146. Liu D, Liu XY, Robinson D et al. Suppression of staphylococcal enterotoxin B-induced toxicity by a nuclear import inhibitor. J Biol Chem 2004; 279: 19239-46.
147. Letoha T, Somlai C, Takacs T et al. A nuclear import inhibitory peptide ameliorates the severity of cholecys-tokinin-induced acute pancreatitis. World J Gastroenterol2005; 11: 990-9.
148. Saika S, Miyamoto T, Yamanaka O et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol 2005; 166: 1393-403.
149. Torgerson TR, Colosia AD, Donahue JP et al.Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998; 161: 6084-92.
150. Takada Y, Singh S, Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 2004; 279: 15096-104.
151. May MJ, D'Acquisto F, Madge LA et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289: 1550-4.
152. Dai S, Hirayama T, Abbas S et al. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004; 279: 37219-22.
153. di Meglio P, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 2005; 52: 951-8.
154. Tas SW, Vervoordeldonk MJ, Hajji N et al. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther2006; 8: R86.
155. Huang J, Sheung J, Dong G et al. High-throughput screening for inhibitors of the E3 ubiquitin ligase APC. Methods Enzymol 2005; 399: 740-54.
156. Doyle SL, Jefferies CA, O'Neill LA. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem 2005; 280: 23496-501.
157. McInnes C. Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel 2006; 9: 339-47.
158. Mansell A, Smith R, Doyle SL et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006; 7: 148-55.
159. Tran EJ, Wente SR. Dynamic nuclear pore complexes: life on the edge. Cell 2006; 125: 1041-53.
160. Zhao LJ, Zhu H. Structure and function of HIV-1 auxiliary regulatory protein Vpr: novel clues to drug design. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 265-75.
161. Wakamatsu K, Nanki T, Miyasaka N et al. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005; 7: R1348-59.
162. Tas SW, Adriaansen J, Hajji N et al. Amelioration of arthritis by intraarticular dominant negative Ikkbeta gene therapy using adeno-associated virus type 5. Hum Gene Ther 2006; 17: 821-32.
163. Lu H, Hachida M, Enosawa S et al. Immunosuppressive effect of triptolide in vitro. Transplant Proc 1999; 31: 2056-7.
164. Suarez-Almazor ME, Belseck E, Shea B et al. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000: CD000958.
165. Breuer-McHam J, Simpson E, Dougherty I et al.Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents. Photochem Photobiol 2001; 74: 805-10.
166. A phase 1/2 multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety of repeated topical application of three concentrations of NF-kappaB decoy in adults with mild-to-moderate atopic dermatitis/http://clinicaltrials.gov/ct/show/NCT00153337?order=1 accessed 12, April 2007.
167. Tomita T, Takeuchi E, Tomita N et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynu-cleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532-42.
168. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2004: CD000189.
169. Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs diseasemodifying therapy. Best Pract Res Clin Rheumatol2006; 20: 539-57.
170. Moutsopoulos NM, Angelov N, Sankar V et al.Immunological consequences of thalidomide treatment in Sjogren's syndrome. Ann Rheum Dis 2006; 65: 112-14.
171. Adams A, Lehman TJ. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 612-16.